Hana Chen-Walden
Plus aucun poste en cours
Profil
Hana Chen-Walden worked as the Director-International Regulatory Affairs at Covalent Group, Inc. from 2000 to 2003.
She then served as the Chief Medical Director at Boston Therapeutics, Inc. and as an Independent Director at BioXyTran, Inc. Dr. Chen-Walden holds a doctorate degree from Tel-Aviv University.
Anciens postes connus de Hana Chen-Walden
| Sociétés | Poste | Fin |
|---|---|---|
| BIOXYTRAN, INC. | Directeur/Membre du Conseil | 19/04/2024 |
| Covalent Group, Inc. | Conseiller Juridique Général | 01/01/2003 |
| NANOMIX CORPORATION | Directeur Technique/Scientifique/R&D | - |
Formation de Hana Chen-Walden
| Tel-Aviv University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOXYTRAN, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
| Covalent Group, Inc. | Commercial Services |
